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Key findings 
Rating the certainty of the body of evidence (quality of evidence or confidence in estimates) 
on the domains imprecision, inconsistency and publication bias for test accuracy studies 
shares the fundamental logic of the GRADE approach for intervention, prognostic or other 
studies but requires different operationalization.   
What this adds to what is known? 
Evidence evaluation will often begin with an evidence synthesis - ideally a systematic review 
or health technology assessment - and the rating of certainty in test accuracy includes 
assessing inconsistency, imprecision, publication bias and other domains. In this part 2 of 
GRADE guidance 21, we describe the judgments on these domains and across a body of 
evidence using examples from how GRADE has been applied to test accuracy studies in 
Cochrane and other reviews as well as World Health Organization and other guidelines.  
What are the implications, what should change now? 
Further work is needed for better operationalization of the domain imprecision and 
domains that may lead to increasing the certainty. However, investigators interested in 
using the GRADE for diagnostic and healthcare related tests should consider the guidance 
offered in this article for the corresponding domains and how the information is presented 
in evidence profiles and summary of findings tables.   
 
  
GRADE detailed series - JCE  
GRADE Guidelines: Diagnosis I                                               Version 20190716 
GRADE Article 21 diagnosis_I  part 2 20191128 revised clean.docx  4 
 
Abstract 
Objectives: This article provides updated GRADE guidance about how authors of systematic 
reviews and health technology assessments (HTA) and guideline developers can rate the 
certainty of evidence (also known as quality of the evidence or confidence in the estimates) 
of a body of evidence addressing test accuracy (TA) on the domains imprecision, 
inconsistency, publication bias and other domains. It also provides guidance for how to 
present synthesized information in evidence profiles and summary of findings tables.  
Study Design and Setting: We present guidance for rating certainty in TA in clinical and 
public health and review the presentation of results of a body of evidence regarding tests.  
Results: Supplemented by practical examples, we describe how raters of the evidence can 
apply the GRADE domains inconsistency, imprecision, and publication bias to a body of 
evidence of TA studies.   
Conclusions:  Using GRADE in Cochrane and other reviews as well as World Health 
Organization and other guidelines helped refining the GRADE approach for rating the 
certainty of a body of evidence from TA studies. While several of the GRADE domains (e.g., 
imprecision and magnitude of the association) require further methodological research to 
help operationalize them, judgments need to be made on the basis of what is known so far. 
 
Key words:  GRADE, diagnosis, tests, test accuracy, certainty of evidence, diagnostic 
accuracy, guidelines, systematic reviews, HTA 
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In part 1 of this 21
st
 article in the GRADE guidance series in the Journal of Clinical 
Epidemiology we described the unique challenges about rating the initial study designs, risk 
of bias and indirectness in studies about test accuracy (TA).(1)  We also introduced three 
examples of questions about the use of tests to which we will refer to also in this article (Box 
1).(1-3) In this part 2 of GRADE guidance 21, we will describe how authors of systematic 
reviews and health technology assessments (HTAs) and guideline developers using GRADE 
can address the certainty (in this series also referred to as quality or confidence) in a body of 
evidence from test accuracy (TA) studies focusing on the domains inconsistency, 
imprecision, publication bias and domains that may increase our certainty. With regards to 
HTA, we refer to the rating of the certainty of TA results from a body of evidene that may be 
used for other aspects of HTA, such as modelling and cost analyses. This article also 
describes how authors of SR and HTA can present the results of an assessment to decision 
makers and it supplements our previous work addressing GRADE for diagnostic questions 
and the GRADE Evidence to Decision Frameworks for tests.(2, 4, 5)  
 
Box 1. Examples of questions about tests 
Example 1: In women at risk for cervical intraepithelial neoplasia (CIN) in low and middle-
income settings, what is the impact of testing for presence of human papilloma virus 
(HPV) instead of VIA on patient and population important outcomes?(6) 
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Population: women at risk of cervical cancer in low and middle-income countries 
Role: replacement test 
Setting: clinics in low and middle income countries 
Intervention: one-time screening with HPV and treatment for cervical intraepithelial 
neoplasia 
Comparison: VIA and treatment for cervical intraepithelial neoplasia  
Purpose and role of test: diagnosis and replacement of no testing  
Outcomes: death from cervical cancer, cervical cancer incidence, CIN recurrence, major 
bleeding, premature delivery, infertility, major and minor infections, unnecessary treatment 
and burden, cervical cancer detection during screening 
 
Example 2 (short form focusing on patient outcomes): In patients suspected of cow’s milk 
allergy (CMA), what is the impact of skin prick tests versus an oral food challenge with 
cow’s milk on mortality from allergic reactions, allergic reactions, development of other 
allergies.(7) 
Participants: patients suspected of CMA  
Role: replacement test  
Setting: specialized clinics 
Index (new) test (intervention): IgE skin prick test  
Reference test (comparison): no IgE skin prick test 
Outcome: test accuracy with health outcome descriptors for the test positives and negatives 
Example 3 (test accuracy focused): In patients presumed to have tuberculous (TB) 
meningitis, what is the accuracy of Xpert – a nucleic acid amplification test (NAAT) – for 
the diagnosis of TB meningitis? 
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Participants: patients suspected of having TB meningitis 
Prior testing: patients who received Xpert testing may first have undergone a health 
examination (history and physical examination) and possibly a chest radiograph 
Role: replacement test for usual practice 
Settings: primarily tertiary care centres (the index test was run in reference laboratories) 
Index (new) test (intervention): Xpert  
Reference test (comparison): culture 
Outcome: test accuracy 
 
2.0 The GRADE certainty domains inconsistency, imprecision and publication bias 
We continue our description of the rating of the certainty by domain and across domains 
from part 1 of this article beginning with inconsistency.(1)  
2.1. Certainty of the evidence - inconsistency 
Important unexplained inconsistency of the results across studies may decrease certainty of 
the evidence. Raters should evaluate estimates for sensitivity and specificity separately. As 
for intervention studies, raters should consider meta-analyses when the evidence would 
support them.  Judgments of the extent of heterogeneity are based on similarity of the point 
estimates, extent of overlap of confidence intervals, variance estimates in random effects 
meta-analysis and statistical criteria including tests of heterogeneity.  Any role of I
2
 in 
assessing heterogeneity in meta-analyses of TA requires further exploration in TA studies 
but it comes with similar limitation as in intervention studies.  
 
2.1.1. Examples for inconsistency 
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In our tuberculous meningitis example, although the sensitivity estimates ranged from 33% 
to 100%, the absence of concentrating the sample in preparing the CSF specimen in certain 
settings could explain some of the heterogeneity (higher sensitivity in concentrated 
samples).(8) Overall the confidence intervals were overlapping for all but one study (Figure 
1). Specificity was similar across the studies. The raters did not lower the certainty for 
inconsistency (Table 1).  
Insert Table 1 approximately here 
 
Steingart and colleagues’ conducted a systematic review evaluating commercial serological 
tests for the diagnosis of pulmonary and extrapulmonary tuberculosis. For extrapulmonary 
tuberculosis, they reported sensitivity values from 0% to 100%, and specificity values from 
59% to 100%.  This variability was sufficiently great that, in the presence of non-overlapping 
confidence intervals and limited explanation for the inconsistency (e.g. identity of the 
commercial test, antibody detected and site of extrapulmonary TB), the authors chose not 
to derive summary accuracy estimates (Figure 2) and rated down for inconsistency.(9) 
While the previous two examples represent debatable exercises of judgment, less 
challenging examples exist.  For instance, consider the investigation of the accuracy of T-
SPOT.TB, an interferon-gamma release assay, for active tuberculosis in people presumed to 
have tuberculosis without HIV infection (Figure 3). Here, similar point estimates and 
overlapping confidence intervals support the judgment not to rate down for inconsistency.   
 
When differences in the populations enrolled, the index test or reference test applied, or 
the outcomes measured, explain inconsistency in the test accuracy estimates, presenting 
results in subgroups is often appropriate. Variability in the investigators’ choice of test 
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thresholds may, for instance, explain heterogeneity and be elucidated in an receiving 
operarator characteristics (ROC) analysis.  Ideally, inconsistency should be assessed by using 
clearly defined thresholds that either resemble healthcare practice or will be used to guide 
practice.  For example, the variability in thresholds used to describe pleural effusion as 
being of cardiac origin based on pro-brain natriuretic peptide (pro-BNP), explained some of 
the inconsistency in the sensitivity and specificity observed in a systematic review evaluating 
the utility of this test.(10) 
 
2.2. Certainty of the evidence - imprecision 
Wide confidence intervals for estimates of test accuracy or true and false positive and 
negative rates can reduce the certainty of the evidence or diagnostic odds ratio (DOR) or 
another accuracy measure.  Here, we focus on the confidence intervals (CI) around 
sensitivity and specificity (note that the imprecision may also be expressed as credible 
intervals). What is wide enough to rate down is, however, a matter of judgement, and these 
decisions may vary depending on the context.(11)  
 
For systematic review authors, imprecision judgments can be based on both the width of 
the confidence interval (CI) and the number of participants in the studies. The CI depend on 
the number of events; for sensitivity it is the number of diseased persons and the number of 
test positives; for the specificity it is the number of non-diseased persons and the number of 
test-negatives. In contextualized settings, i.e. when decision making is influenced by 
weighing the TP, FN, TN and FP against each other and the downstream consequences, 
raters should set thresholds for the confidence intervals that reflect the implications for 
people or patient management. When the boundaries of the CI include values that may lead 
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to different conclusions of the test’s value the certainty of the evidence may be lowered. 
This implies that a relatively narrow CI may still be too wide to make a firm conclusion. For 
example, if review authors or a guideline panel agrees beforehand that a sensitivity of 0.8 
would be the lowest acceptable sensitivity for a certain situation, then a CI that runs from 
0.72 to 0.88 may be too wide to conclude whether use of the test provides more benefits 
than harms. On the other hand, a CI between 0.82 and 0.92 may be considered narrow 
enough to draw a conclusion. For decision makers, this should be done by translating the 
estimates for sensitivity and specificity (and their confidence intervals) to absolute numbers 
of TP, FP, FN, TN (and any upper and lower limits around these) for assumed prevalences. 
For example, if the average number of people tested per year for a condition is 1000, and 
the expected prevalence among this population is to be 1%, then 10 people are expected to 
have the disease and in that case a wider CI around sensitivity may lead to less concern 
about imprecision than when the prevalence is around 40% because a fairly narrow 
confidence interval for sensitivity may lead to a wide CI for the TP. 
 
2.2.1. Examples for imprecision 
Based on the pooled estimates of sensitivity and specificity, Kohli and colleagues calculated 
the estimates of TP, FN, TN and FP for different prevalences of tuberculous meningitis (Table 
1).  Based on 433 patients in 29 studies, they judged the limits of the credible intervals for 
the TP and FN to be sufficiently wide to warrant rating down for imprecision; in contrast, 
they found that the limits for the TN and FP were sufficiently narrow that rating down was 
unnecessary.  For our example about diagnosis of CMA (Table 2), the CI were sufficiently 
narrow not to warrant downgrading.   
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2.3. Certainty of the evidence - Publication bias 
Generally, raters should make publication bias judgments using the same criteria as in 
therapeutic studies: for-profit interest, the presence of only studies that produce precise 
estimates of high accuracy despite small sample size, and knowledge about studies that 
were conducted but are not published.  Although high suspicion of publication bias will 
decrease our certainty in TA results, little is known about the actual existence of publication 
bias in TA studies. Applying widely used tests for funnel plot asymmetry (e.g Egger’s or 
Begg’s tests) in test accuracy systematic reviews is likely to result in rating down for 
publication bias more frequently than appropriate.  For instance, study size may correlate 
with test accuracy as a result of patients’ or study characteristics rather than publication 
bias.  
 
Other tests (e.g. Deeks’ test or the trim and fill method) may be more appropriate for 
testing publication bias in TA systematic reviews. (12-14)  The trim and fill method, in 
particular, has advantages that include providing an estimate of the unbiased TA and an 
intuitive visual display that includes both the observed studies and the imputed studies, 
allowing authors to visually inspect how much TA changes when the imputed studies are 
included. If this change is trivial, then there is no need to rate down certainty for publication 
bias.  
 
A special situation of publication bias may occur with non-inferiority test accuracy studies. In 
that case, accuracy of a new index test compared with the reference test is based on the 
difference in the paired partial area under the ROC curve.  One can test this difference with 
Bayesian statistical methods that result in assessing statistical significance.(15) Because of 
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the ability to assess statistical significance, this design may be more susceptible to not 
publishing negative findings, which theoretically can lead to publication bias. Given the 
limitations of all the available statistical models and methods to test for publication bias in 
TA studies, confident inferences that publication bias exists may be restricted to knowledge 
that unpublished TA studies exist.  The lack of a standardized method to register TA studies, 
however, makes such knowledge difficult to obtain. 
 
2.3.1 Examples for publication bias 
Kohli and coauthors did not rate down for publication bias despite concerns about for-profit 
interest and small studies. This was due to the comprehensiveness of the literature search 
and the extensive outreach to TB researchers did not identify unpublished studies. 
In a systematic review that assessed the accuracy of magnetic resonance imaging (MRI) in 
identifying liver iron overload in patients with hereditary hemochromatosis, 
hemoglobinopathy, or myelodysplastic syndrome the authors suspected publication bias. 
(16) In the regression test for funnel plot asymmetry (Deek’s test), the P-value for the slope 
coefficient was 0.07. (16) Murad and colleagues also used Deeks’ funnel plot asymmetry 
tests and visual inspection of funnel plots in their review of Fractional Exhaled Nitric Oxide 
(FeNO) in Asthma Management.  The authors described potential publication bias for 
cutoffs<20, and no indication of publication bias for cutoffs 20-30 (Figure 4).(17) 
 
3.0. Certainty of the evidence - upgrading for test-outcome relations, large estimates of TA 
and residual plausible bias and confounding 
Upgrading may be relevant for rating a body of evidence from studies of TA. Certainty in TA 
may increase if the ROC curve shows a clear and consistent sensitivity-specificity 
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relationship (the diagnostic equivalent of a dose effect).  The strongly increased likelihood of 
acute myocardial infarction with increasing levels of troponin T increases our confidence in 
the diagnostic properties of this test, that is a strong correlation between increasing test 
values and the likelihood and severity of disease as opposed to the mathematical 
phenomenon of a simple increase in the likelihood because of choosing different cut-offs for 
the test values.(18) Very high accuracy of a test, and the presence of minimal opposing 
residual confounding (19) might also increase one’s confidence in the usefulness of the test. 
Compared with the effects on the certainty in therapeutic interventions in observational 
studies, the methods to determine whether the evidence warrants rating up on a particular 
domain is, however, less well established for tests and requires further theoretical and 
empirical work. Even amongst the authors of this article, there is no agreement if and how, 
for example, dose-effects play a role in assessing the certainty in estimates in TA studies. 
 
3.1. Examples for upgrading 
For example, evidence suggesting a threshold dependent identification of false negatives 
and false positives in the diagnosis of asthma with FeNO may increase the certainty of the 
test accuracy studies (Figure 5).   
 
4.0. Arriving at a bottom line for the certainty of the evidence  
Tables 1 and 2 show the assessment of the certainty in the evidence of TA and the summary 
of findings (SoF) table for examples 2 and 3 (Box 1).  Kohli and colleagues rated down the 
certainty for TP and FN (sensitivity) for imprecision but not for TN and FP (specificity) (Table 
1). The included accuracy studies were well planned and executed, the systematic review 
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authors undertook investigations to explain inconsistency, and there was little reason for a 
high suspicion of publication bias.  The authors judged, however, that credible intervals for 
the sensitivity of the test were excessively wide and rated the overall certainty moderate for 
sensitivity and high for specificity. This example demonstrates that the certainty frequently 
differs for the accuracy outcome pairs TP and FN (sensitivity) compared to the FP and TN 
(specificity). 
In the example evaluating tests for CMA (Table 2), most studies enrolled highly selected 
patients with atopic eczema or gastrointestinal symptoms, no study reported if an index test 
or a reference standard were interpreted without knowledge of the results of the other test 
and it is very likely that those interpreting results of one test knew the results of the other. 
In addition, all except for one study that reported withdrawals did not explain why patients 
were withdrawn. The systematic review authors, therefore, rated down for risk of bias. They 
also rated down for imprecision for TP, FN, TN and FP for an overall rating of low certainty. 
 
5.0 Presentation of results – Evidence Profiles and Summary of Findings Tables  
Clear presentations of information about diagnostic tests in evidence summaries helps 
ensure transparency for decision-makers. We described evidence profiles and SoF tables in 
prior articles in this series.(20)  When the focus in on TA, the presentation format differs 
from presentation of questions about therapy or interventions.  
 
GRADE identified three types of layers of evidence summaries that might be useful and can 
be developed in GRADE’s official app GRADEpro: First, simple SoF tables and evidence 
profiles that provide information about TA alone (we refer to this as layer 1, illustrated in 
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Tables 1 and 2).  Tables may also include basic information regarding other features related 
to the test or test strategy facilitating decision-making such as direct complications of a test 
that can be derived from accuracy studies (layer 2). Tables that provide the information as 
patient-important outcomes and include explicit judgments about the desirable and 
undesirable health effects of tests (layer 3) are useful during the process of making 
recommendations.(3) The format of Tables 1 and 2 and the corresponding interactive SoFs 
(iSoFs) are based on the results of testing of alternative presentation formats with various 
user groups.(21) Systematic review authors may sometimes use layer 2 to describe the 
direct consequences of a test apart from TA. For example, the direct undesirable effects of a 
test such as anaphylactic reactions from radiological contrast dye, inconclusive results or 
direct burden from the test may be described to facilitate decision making.   
 
Layer 3 includes information for health outcomes following a decision analysis of the various 
scenarios that result in patient or population important outcomes. We described layer 3 in 
other articles in this series that address recommendations about diagnostic and other tests 
and strategies.(2, 3)  
 
Limitations of Level 1 SoF Table format includes challenges in managing continuous or multi-
level tests easily. These results are best presented through interactive SoF (iSoF) tables in 
GRADEpro to which we provide hyperlinks in tables 1 and 2. The separate columns for 
true/false positive/negatives are most useful for an analysis of consequences of test 
outcomes (when indirectness is a problem) but also introduce redundancy. However, our 
user testing suggests that the current format is helpful in summarizing results in systematic 
reviews and included presentation in the setting of guideline panels.  
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The GRADE approach to rating the certainty of evidence for TA is comprehensive and 
transparent.  We have presented an overview of this approach, provided examples and 
reviewed the presentation of results of a body of evidence for TA studies in this and the 
prior article (part 1). Although several of the domains (e.g., imprecision, publication bias and 
magnitude of the association) will benefit from further elaboration in methodological 
research, they have been applied in many systematic reviews and guidelines.  
 
In the next article in this series we will describe how the information from test accuracy can 
inform the development of recommendations, based on the recognition that test results can 
be surrogate markers for patient important outcomes.(3) We will also provide alternative 
ways of presenting this information during the development of recommendations and to 
users of guidelines. In addition, in another article, the GRADE working group provided a 
conceptual approach to defining the certainty of evidence for test accuracy studies.(22) 
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Table 1. Summary of findings table and evidence profile summarizing diagnostic test accuracy studies informing the question “Should Xpert be 
used to diagnose TB meningitis in people suspected of having the disease? (8)” Non-contextualized certainty of the evidence in test accuracy 
rating (without rating the indirectness stemming from the link between accuracy data and patient outcomes). For an interactive version in 
GRADEpro see this hyperlink iSoF Table 1 (also including a plain language summary)  
 
Summary of Findings Table: Should Xpert be used to diagnose TB meningitis in people suspected of having the disease? 
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Evidence profile: Should Xpert be used to diagnose TB meningitis in people suspected of having the disease? 
Sensitivity  0.71 (95% CI: 0.61 to 0.80) 
Specificity  0.98 (95% CI: 0.97 to 0.99) 
 
 
Prevalences  1% 5% 10% 
  
Outcome 




Factors that may decrease certainty of evidence Effect per 1,000 patients tested 
Test accuracy 
CoE Risk of 
bias 












(patients with TB 
meningitis)  
29 studies 
433 patients  
cross-sectional 
(cohort type 









classified as not having 
TB meningitis)  
3 (2 to 4) 14 (10 to 20) 29 (20 to 39) 
True negatives 
(patients without TB 
meningitis)  
29 studies 
3341 patients  
cross-sectional 
(cohort type 
accuracy study)  
not 
serious  
not serious  not serious  not serious  none  970 (960 to 
978) 
931 (922 to 
939) 






classified as having TB 
meningitis)  
20 (12 to 30) 19 (11 to 28) 18 (11 to 27) 
Explanations 
a. As assessed by QUADAS-2, for the reference standard domain there were only four studies (14%) that had unclear risk of bias because specimens underwent decontamination. We did not downgrade.  
b. For indirectness, regarding applicability, for the patient selection domain, we considered most studies to have unclear concern. Three studies had high concern because patients were evaluated as inpatients in tertiary care centres; 
however, we recognize this is how some patients may present in practice. For the index and reference test domains, we considered most studies to have low concern for applicability. We did not downgrade.  
c. For individual studies, sensitivity estimates ranged from 33% to 100%. We thought that low TB prevalence and absence of concentration in preparing the cerebrospinal fluid specimen could explain some of the heterogeneity in sensitivity 
results. We did not downgrade.  
d. The wide CrI around true positives and false negatives may lead to different decisions depending on which credible limits are assumed. We downgraded one level.   
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Table 2. Summary of Findings table and evidence profile summarizing diagnostic test accuracy studies informing the question “Should skin 
prick tests be used for the diagnosis of IgE-mediated cow’s milk allergy (CMA) in patients suspected of CMA?”. Non-contextualized certainty of 
the evidence in test accuracy rating (without rating the indirectness stemming from the link between accuracy data and patient 
outcomes).(23) For an interactive version in GRADEpro with case descriptors see this hyperlink iSoF Table 2 (also including a plain language 
summary)  
 
Summary of Findings Table: Should skin prick tests be used to diagnose IgE-mediated cow’s milk allergy (CMA) in patients suspected of CMA? 
Patient or population : patients suspected of CMA 
Setting : children suspected of IgE-mediated CMA 
New test : [comparator test] | Cut-off value : 
Reference test : oral food challenge | Threshold : anaphylaxis, burden on time and anxiety for family, exclusion of milk and use of special formula 
Pooled sensitivity : 0.67 (95% CI: 0.64 to 0.70) | Pooled specificity : 0.74 (95% CI: 0.72 to 0.77) 
Test result 
Number of results per 1,000 patients tested (95% CI) 
Number of participants 
(studies) 
Certainty of the 
Evidence (GRADE) Prevalence 10% 
Typically seen in 
Prevalence 40% 
Typically seen in 
Prevalence 80% 
Typically seen in 
True positives 67 (64 to 70) 268 (256 to 280) 536 (512 to 560) 2302 
(23) 
⨁⨁◯◯ 
LOW a,b False negatives 33 (30 to 36) 132 (120 to 144) 264 (240 to 288) 
True negatives 666 (648 to 693) 444 (432 to 462) 148 (144 to 154) 2302 
(23) 
⨁⨁◯◯ 
LOW a,b False positives 234 (207 to 252) 156 (138 to 168) 52 (46 to 56) 
CI: Confidence interval 
Evidence Profile 
Question: Should skin prick tests be used to diagnose IgE-mediated cow’s milk allergy (CMA) in patients suspected of CMA? 
Sensitivity  0.67 (95% CI: 0.64 to 0.70) 
Specificity  0.74 (95% CI: 0.72 to 0.77) 
 
 
Prevalences  10% 40% 80% 
  
Outcome 





























not serious  serious b not serious  none  67 (64 to 70) 268 (256 to 
280) 
536 (512 to 
560) 
⨁⨁◯◯ 
GRADE detailed series - JCE  
GRADE Guidelines: Diagnosis I                                               Version 20190716 
GRADE Article 21 diagnosis_I  part 2 20191128 revised clean.docx  22 
 
Outcome 





















cow’s milk allergy (CMA))  patients  accuracy study)  LOW  
False negatives 
(patients incorrectly 
classified as not having IgE-
mediated cow’s milk allergy 
(CMA))  
33 (30 to 36) 132 (120 to 
144) 











accuracy study)  
serious 
a 
not serious  serious b not serious  none  666 (648 to 
693) 
444 (432 to 
462) 






classified as having IgE-
mediated cow’s milk allergy 
(CMA))  
234 (207 to 
252) 
156 (138 to 
168) 
52 (46 to 56) 
Explanations 
a. Most studies enrolled highly selected patients with atopic eczema or gastrointestinal symptoms, no study reported if an index test or a reference standard were interpreted without knowledge of the results of the other test, but it is very 
likely that those interpreting results of one test knew the results of the other; all except for one study that reported withdrawals did not explain why patients were withdrawn.  
b. Estimates of sensitivity ranged from 10% to 100%, and specificity from 14% to 100%; we could not explain it by quality of the studies, tests used or included population.  
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Figure 2. Forest plots of sensitivity and specificity of commercial serological tests for 
extrapulmonary TB, all studies.(9)  
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Figure 3. Sensitivity of T-SPOT.TB in HIV-negative people with confirmed active 
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Rating the certainty of the body of evidence (quality of evidence or confidence in estimates) on 
the domains imprecision, inconsistency and publication bias for test accuracy studies shares the 
fundamental logic of the GRADE approach for intervention, prognostic or other studies but 
requires different operationalization.   
What this adds to what is known? 
Evidence evaluation will often begin with an evidence synthesis - ideally a systematic review or 
health technology assessment - and the rating of certainty in test accuracy includes assessing 
inconsistency, imprecision, publication bias and other domains. In this part 2 of GRADE 
guidance 21, we describe the judgments on these domains and across a body of evidence using 
examples from how GRADE has been applied to test accuracy studies in Cochrane and other 
reviews as well as World Health Organization and other guidelines.  
What are the implications, what should change now? 
Further work is needed for better operationalization of the domain imprecision and domains 
that may lead to increasing the certainty. However, investigators interested in using the GRADE 
for diagnostic and healthcare related tests should consider the guidance offered in this article 
for the corresponding domains and how the information is presented in evidence profiles and 
summary of findings tables.   
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